Aug 13, 2020
MicuRx Announces CARB-X US$7.78 Million Funding for Development of MRX-8
Jun 17, 2020
Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections
May 19, 2020
MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3 - a Potential New Gold Standard, First-line Treatment for Clostridium difficile Infection (CDI)
May 11, 2020
Vibativ® Sustained Potency Confirmed In Two Surveillance Studies
May 06, 2020
Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens
Jan 15, 2020
Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection
Nov 13, 2019
CDC releases 2019 AR Threats Report
Nov 04, 2019
Acurx Pharmaceuticals to Present at Two Prominent International Healthcare Conferences
Oct 22, 2019
Qpex Biopharma and Brii Biosciences Enter Into a Strategic Collaboration to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China
Oct 11, 2019
Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer
Oct 10, 2019
MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
Oct 03, 2019
Acurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences
Sep 27, 2019
Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek(TM) 2019
Sep 25, 2019
Qpex Biopharma to Present its Anti-infective Portfolio at IDWeek 2019
Sep 18, 2019
Skytron and Surfacide Combine to Create the Strongest Portfolio of UVC Infection Prevention in the Healthcare Industry
Sep 11, 2019
ANI Pharmaceuticals Announces Launch of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL
Sep 03, 2019
Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa
Aug 28, 2019
Research Conducted by the University of Birmingham Finds New Antimicrobial Coating Could be Key in Fight Against Hospital-Acquired Infections
Aug 14, 2019
FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
Aug 14, 2019
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis